In this study, clinicians used a novel high-precision radiation strategy with Elekta Unity to monitor and adapt treatment as the tumor evolves over the 3-6 week therapy. By adapting to the tumor’s changing shape, clinicians were able to significantly reduce radiation exposure to healthy brain tissue as compared to the standard of care. Importantly, Detsky reported that this brain-sparing approach does not compromise control of high-grade gliomas (HGG), the most common and aggressive primary brain tumors in adults.

“MR-guided adaptive radiation may represent the first major advance in radiation treatment for high-grade gliomas in over 25 years,” says Detsky. “By integrating serial MRI imaging into the paradigm, we have been able to see a significant reduction in the volume of brain we’re irradiating when treating high-grade gliomas, which could significantly improve the tolerability of treatment and quality of life for patients.”

Challenge the belief that HGGs are static

The results of the study, which were presented as part of the scientific program during the 2024 American Society for Radiation Oncology (ASTRO) Annual Meeting, challenge the belief that HGGs are static – that there is no meaningful change in shape of brain tumors from the time the initial radiation plan is generated to the end of the treatment course.

The UNITED trial

The UNITED trial was designed to compare how often patients experienced tumor recurrences at the edge of the radiation target using the new more precise approach against the historical standard. Prior research suggested that using a less precise approach was associated with recurrences at the target edge in about 1 in 9 patients (11%). In UNITED, only about 1 in 25 patients (4%) patients experienced tumor recurrence at the edge of the target, exceeding expectations.

When we started developing clinical treatments for Elekta Unity with the other founding members of the MR-Linac Consortium, we were all confident that it would be a game changer for cancers that move with breathing, like liver and pancreas cancers, but we were less certain about how important Unity would be for brain tumors.

“When we started developing clinical treatments for Elekta Unity with the other founding members of the MR-Linac Consortium, we were all confident that it would be a game changer for cancers that move with breathing, like liver and pancreas cancers, but we were less certain about how important Unity would be for brain tumors,” says Arjun Sahgal, Chief of Radiation Oncology at Sunnybrook. “It is enormously gratifying to see Unity and UNITED move the needle for brain tumor patients too.”